|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Affymetrix, Inc. announced that it is making many of its issued patents in microarrays, available for licensing and, in selected areas, for sale to those using and commercializing microarray-centered technologies. The patents include intellectual property in areas such as DNA and protein arrays, scanner/detector technology, and microfluidics, as well as a broadened portfolio of patents related to the use of beads to measure nucleic acids or peptide binding for genomic analysis. AngioGenex Inc. and BioCheck Inc. are collaborating to develop cancer diagnostic and prognostic products based on AGx's Id-gene platform technology for the measurement of Id- proteins in blood and tumor tissue. A recently approved Phase I SBIR grant will provide seed funding for the collaboration. CalbaTech, Inc. is developing a respiratory pathogen chip to detect the presence of respiratory pathogens including influenza viruses, rhinoviruses, coronaviruses (including the SARS virus), RSV, Chlamydia pneumoniae, and other commonly occurring pathogens. Genaissance Pharmaceuticals, Inc. has introduced a genetic test for cardiac ion channel mutations, which will include mutations responsible for causing Familial Long QT and Brugada Syndromes, two causes of sudden cardiac death. Genaissance will conduct the genetic test in its CLIA-licensed laboratory. Myriad Genetics, Inc. has licensed exclusive US rights to detect mutations in the Mut Y Homolog (MYH) gene, a new colon cancer gene. The test will be added to the COLARIS product line. MYH is a DNA repair gene that corrects DNA basepair mismatch errors in the genetic code prior to replication. Tm Bioscience Corporation has launched its Tag-It Cystic Fibrosis ASR products for the detection of mutations in the gene associated with Cystic Fibrosis. The test can identify 39 mutations and 4 variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: May 03, 2004 |
![[Page Banner Image]](images/hmole.gif){kind=small}
